Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Works To Ease “Traumatic” Advisory Committee Process – Ganley

This article was originally published in The Tan Sheet

Executive Summary

Recognizing that planning and conducting advisory committee meetings can be "traumatic" for both government and industry, FDA is taking steps to improve the process, said Charles Ganley, the head of the agency's OTC drugs program

You may also be interested in...



OTC Basics Included In Training To Improve FDA Advisory Committee Process

FDA will include basic over-the-counter drug processes in training this week for all advisory committee members

OTC Basics Included In Training To Improve FDA Advisory Committee Process

FDA will include basic over-the-counter drug processes in training this week for all advisory committee members

OTC Basics Included In Training To Improve FDA Advisory Committee Process

FDA will include basic over-the-counter drug processes in training this week for all advisory committee members

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel